Inhibit GSK-3beta or there's heartbreak dead ahead.
Numerous signaling pathways have been shown to mediate cardioprotection, but the end effectors that mediate protection are only beginning to be elucidated. Numerous cardioprotective drugs are shown to converge on glycogen synthase kinase-3beta (GSK-3beta). The phosphorylation and inhibition of GSK-3beta lead to inhibition or delayed activation of the mitochondrial permeability transition, a key regulator of apoptosis.
Murphy
Elizabeth
E
Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, North Carolina 27709, USA. murphy1@niehs.nih.gov
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D002316:Cardiotonic Agents / Q000494:pharmacology; D038362:Glycogen Synthase Kinase 3 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D008928:Mitochondria / Q000502:physiology; D010766:Phosphorylation; D015398:Signal Transduction / Q000502:physiology
D002316:Cardiotonic Agents; C000605506:GSK3B protein, human; D000071679:Glycogen Synthase Kinase 3 beta; D038362:Glycogen Synthase Kinase 3